trending Market Intelligence /marketintelligence/en/news-insights/trending/sbl2b_f7rc8doak58mb_g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Galectin Therapeutics closes private placements

Mining Exploration Insights – January, 2020

Despite Fewer CUSIP Requests in December, Overall Total Increased Year Over Year

Case Study: Leveraging a Comprehensive Project Finance Credit Assessment Scorecard

Traditional Multichannel Video Plummets In Rural Areas

Galectin Therapeutics closes private placements

Galectin Therapeutics Inc. raised $3 million in a private placement of its common stock.

The company separately closed on an additional sale of its series B-3 preferred stock, resulting in about $1 million of additional proceeds.

In the placement of common stock, one existing investor and a new investor purchased 2,814,230 common shares and received warrants for common stock exercisable at $5.00 per share.

Under a Sept. 22 stock purchase agreement, 10X Fund LP purchased 1,008,000 series B-3 preferred shares, which are convertible into 896,997 common shares, for a purchase price of about $1 million. The fund also received warrants for common stock exercisable at $3.00 per share.

Peter Traber, president, CEO and chief medical officer, said in a statement that proceeds from the private placement will provide funding for the company's clinical programs, particularly a clinical trial that will assess the efficacy of Galectin's lead compound GR-MD-02 in patients with NASH cirrhosis, liver inflammation and damage caused by a buildup of fat in the liver.